Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Simvastatin Attenuated Tumor Growth in Different Pancreatic Tumor Animal Models

Open access

Abstract

Newly diagnosed pancreatic cancer increases year by year, while the prognosis of pancreatic cancer has not been very good. Statin drugs were found to have protective effects against a variety of cancers, but their association with pancreatic cancer remains to be clarified. This study used different pancreatic cancer cell lines and in different animal models to confirm the relationship between simvastatin and pancreatic cancer. Flow cytometry and luciferase-based bioluminescent images were used to investigate the cell cycle and tumor growth changes under simvastatin treatment. Simvastatin decreased the MIA PaCa-2 cells, PANC-1 cells, and BxPC-3 cell viability significantly and may arrest the cell cycle in the G0 phase. During in vivo study, subcutaneously implanted simvastatin pre-treated pancreatic cancer cells and intraperitoneally treated simvastatin continuously demonstrated a slower tumor growth rate and decreased the tumor/body weight ratio significantly. In intravenous implant models, implanted simvastatin-pre-treated BxPC-3 cells and cells treated along with simvastatin significantly decreased the tumor growth curve. Implanting the simvastatin-pre-treated pancreatic cells in the subcutaneous model showed better growth inhibition than the intravenous model. These results suggest simvastatin treatment may relate to different signaling pathways in local growth and metastasis. Pancreatic cancer cells presented different growth patterns in different animal-induced models, which could be important for clinical reference when it comes to the relationship of long-term statin use and pancreatic cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph15111408

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The pancreatic cancer cell viability after simvastatin treatment. (A) 50 μM simvastatin treatment significantly decreased the MIA PaCa-2 and PANC-1 cell viability. (B) Reduction of MIA PaCa-2 and PANC-1 cell proliferation after treatment with 50 µM simvastatin. (C) The cell viability assay after different simvastatin concentration treatment in BxPC-3 cells. (D) The cell viability curve after different simvastatin concentration treatment in BxPC-3 cells. (n = 6) ** p < 0.01 when compared to the control group.
Figure 1 The pancreatic cancer cell viability after simvastatin treatment. (A) 50 μM simvastatin treatment significantly decreased the MIA PaCa-2 and PANC-1 cell viability. (B) Reduction of MIA PaCa-2 and PANC-1 cell proliferation after treatment with 50 µM simvastatin. (C) The cell viability assay after different simvastatin concentration treatment in BxPC-3 cells. (D) The cell viability curve after different simvastatin concentration treatment in BxPC-3 cells. (n = 6) ** p < 0.01 when compared to the control group.CC BY · PubMed Central
Figure 2 The cell cycle analysis by flow cytometry indicated the effects of different simvastatin concentration treatments. (A) Cells were treated with different concentration of simvastatin and cell cycle changes were observed using flow cytometry. (B) Statistical results of each phase in cell cycle. The 50 μM simvastatin treatments revealed more G0/G1 phase arrest in MIA PaCa-2 cells. (n = 6).
Figure 2 The cell cycle analysis by flow cytometry indicated the effects of different simvastatin concentration treatments. (A) Cells were treated with different concentration of simvastatin and cell cycle changes were observed using flow cytometry. (B) Statistical results of each phase in cell cycle. The 50 μM simvastatin treatments revealed more G0/G1 phase arrest in MIA PaCa-2 cells. (n = 6).CC BY · PubMed Central
Figure 3 BxPC-3 cell subcutaneously induced pancreatic cancer mice model. (A) Group 1: Implant non-pre-treated cells on left side and pre-treated cells on the right side. (B) Group 2: Implant non-pre-treated cells on the left side and pre-treated cells treated with simvastatin IP after implant on the right side. (C) The tumor growth curve from day 3 to day 37 in group 1. The implanted simvastatin pre-treated cell group had significantly decreased tumor growth from day 19 to day 37 (p < 0.05). (D) The tumor growth curve from day 3 to day 37 in group 2. The implanted simvastatin pre-treated cell group (simvastatin treatment continuously) had significantly decreased tumor growth from day 33 to day 37 (p < 0.05). (E) The tumor growth curve in group 1 and group 2. The pre-treated simvastatin cell implant and intraperitoneal simvastatin treatment after implantation demonstrated a lower growth rate the than non-simvastatin treatment group. (p < 0.05) (n = 8).
Figure 3 BxPC-3 cell subcutaneously induced pancreatic cancer mice model. (A) Group 1: Implant non-pre-treated cells on left side and pre-treated cells on the right side. (B) Group 2: Implant non-pre-treated cells on the left side and pre-treated cells treated with simvastatin IP after implant on the right side. (C) The tumor growth curve from day 3 to day 37 in group 1. The implanted simvastatin pre-treated cell group had significantly decreased tumor growth from day 19 to day 37 (p < 0.05). (D) The tumor growth curve from day 3 to day 37 in group 2. The implanted simvastatin pre-treated cell group (simvastatin treatment continuously) had significantly decreased tumor growth from day 33 to day 37 (p < 0.05). (E) The tumor growth curve in group 1 and group 2. The pre-treated simvastatin cell implant and intraperitoneal simvastatin treatment after implantation demonstrated a lower growth rate the than non-simvastatin treatment group. (p < 0.05) (n = 8).CC BY · PubMed Central
Figure 4 Bioluminescent images in the BxPC-3 cell intravenously induced pancreatic cancer mice models. (A) Group 3: Intravenous non-pre-treated cells that were treated with DMSO after implant. (B) Group 4: Intravenous non-pre-treated cells that were treated with simvastatin after implant. (C) Group 5: Intravenous pre-treated cells that were treated with DMSO after implant. (D) Group 6: Intravenous pre-treated cells that were treated with simvastatin after implant. (E) The tumor growth curve in groups 3, 4, 5, and 6. Group 4 showed a significant decrease from day 12 to day 22 when compared to groups 3, 5, and 6. (p < 0.05) (n = 8).
Figure 4 Bioluminescent images in the BxPC-3 cell intravenously induced pancreatic cancer mice models. (A) Group 3: Intravenous non-pre-treated cells that were treated with DMSO after implant. (B) Group 4: Intravenous non-pre-treated cells that were treated with simvastatin after implant. (C) Group 5: Intravenous pre-treated cells that were treated with DMSO after implant. (D) Group 6: Intravenous pre-treated cells that were treated with simvastatin after implant. (E) The tumor growth curve in groups 3, 4, 5, and 6. Group 4 showed a significant decrease from day 12 to day 22 when compared to groups 3, 5, and 6. (p < 0.05) (n = 8).CC BY · PubMed Central
Figure 5 Xenograft subcutaneous tumor animal model (PANC-1). (A) Gross pictures of tumor size from day 0 to day 28. Control: tumor-induced control; implant pre-treated cells and simvastatin treatment after being induced (I); implant pre-treated cells without simvastatin treatment after being induced (S). (B) The tabular data of three groups. (C) The tumor weight and body weight ratio among the three groups on day 28. The pre-treated simvastatin cell implants and intraperitoneal simvastatin treatments after implantation significantly decreased the tumor weight and body weight ratio. (n = 6) * p < 0.05 when compared to the control group.
Figure 5 Xenograft subcutaneous tumor animal model (PANC-1). (A) Gross pictures of tumor size from day 0 to day 28. Control: tumor-induced control; implant pre-treated cells and simvastatin treatment after being induced (I); implant pre-treated cells without simvastatin treatment after being induced (S). (B) The tabular data of three groups. (C) The tumor weight and body weight ratio among the three groups on day 28. The pre-treated simvastatin cell implants and intraperitoneal simvastatin treatments after implantation significantly decreased the tumor weight and body weight ratio. (n = 6) * p < 0.05 when compared to the control group.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 2

  1. PDQ® Adult Treatment Editorial Board (2022, November 13). PDQ Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment. Bethesda, MD: National Cancer Institute. Updated <10/07/2022>. PMID: 26389340, Available online: https://www.cancer.gov/types/pancreatic/patient/pnet-treatment-pdq.
  2. PDQ® Adult Treatment Editorial Board (2022, November 13). PDQ Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment. Bethesda, MD: National Cancer Institute. Updated <8/19/2022>. PMID: 26389309, Available online: https://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq.

Cited by

See all 13

Metadata

Authors
Chen, C.-Y., Yang, Y.-F., Wang, P. C., Shan, L., Lin, S., Chen, P.-J., Chen, Y.-J., Chiang, H.-S., Lin, J.-T., Hung, C.-F., & Liang, Y.-J.
Affiliations
  • Fu Jen Catholic University (TW)
  • Howard University (US)
Corresponding author
Liang, Yao-Jen
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2022-11-14
Volume
15
Issue
11
Pages
1408
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4309032583
Cited by
13
References
37
Citations by year
2026: 5 · 2025: 5 · 2024: 1 · 2023: 2
FWCI
0.84
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (NIH/NIMHD G12MD007597, NSC MOST—105—2632—B—030—001)
  • Taiwan National Science and Technology Council (NIH/NIMHD G12MD007597, NSC MOST—105—2632—B—030—001)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
simvastatin, pancreatic cancer, statins, tumor growth inhibition, cell cycle arrest, MIA PaCa-2 cells, PANC-1 cells, BxPC-3 cells, subcutaneous xenograft, intraperitoneal implantation, metastasis, anticancer effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simvastatin Attenuated Tumor Growth in Different Pancreatic Tumor Animal Models. https://app.cochat.ai/papers/10.3390/ph15111408
The paper
Chen, C.-Y., Yang, Y.-F., Wang, P. C., Shan, L., Lin, S., Chen, P.-J., Chen, Y.-J., Chiang, H.-S., Lin, J.-T., Hung, C.-F., & Liang, Y.-J. (2022). Simvastatin Attenuated Tumor Growth in Different Pancreatic Tumor Animal Models. Pharmaceuticals. https://doi.org/10.3390/ph15111408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.